A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin ®) in Healthy Chinese Males

ConclusionThis study demonstrated that the pharmacokinetics, safety, and immunogenicity of SCT510 were equivalent to bevacizumab (Avastin®). As a proposed biosimilar drug to bevacizumab, SCT510 was well tolerated in healthy Chinese males.Clinical Trials RegistrationNCT05113511.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research